Skip to content

    Cancer Health Center

    Font Size
    A
    A
    A

    Chronic Myelogenous Leukemia Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (05 / 23 / 2014)

    The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

    Chronic-Phase Chronic Myelogenous Leukemia (CML)

    Recommended Related to Non-Hodgkin's Lymphoma

    Bone Marrow Transplants

    Bone marrow is a spongy material inside your bones where your body makes and stores blood cells. When it’s damaged, it makes too few blood cells and not enough cells for your immune system. A transplant replaces damaged bone marrow with healthy marrow cells. It can cure certain diseases or some types of cancer. It also means a long recovery process and a risk of serious side effects. If you’re thinking about having one, talk with your doctor about all the pros and cons of the transplant.

    Read the Bone Marrow Transplants article > >

    Added text to state that nilotinib-treated patients had a lower rate of treatment-emergent BCR/ABL mutations than did imatinib-treated patients (cited Hochhaus et al. as reference 8).

    Added text to state that a single-center, retrospective analysis of 483 patients with chronic phase CML who were treated with imatinib, dasatinib, or nilotinib indicated that patients who have better than 35% t(9;22)+ cells at 3 months of therapy have inferior event-free, transformation-free, and overall survival rates compared with patients who have better early cytogenetic responses (cited Jain et al. as reference 23).

    Added Tyrosine kinase inhibitor-resistant CML as a new subsection.

    Relapsing Chronic Myelogenous Leukemia (CML)

    Added Jain et al. as reference 4.

    Added text to state that for patients resistant to the tyrosine kinase inhibitors, omacetaxine mepesuccinate has shown a hematologic response rate of 67% and a median progression-free survival of 7 months in a small, phase II study of 46 patients (cited Cortes et al. as reference 21 and level of evidence 3iiiDiv).

    This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

    This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http:// cancer .gov or call 1-800-4-CANCER.

    WebMD Public Information from the National Cancer Institute

    Last Updated: May 28, 2015
    This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
    1
    Next Article:

    Today on WebMD

    Colorectal cancer cells
    New! I AM Not Cancer Facebook Group
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Ovarian cancer illustration
    Real Cancer Perspectives
     
    Jennifer Goodman Linn self-portrait
    Blog
    what is your cancer risk
    HEALTH CHECK
     
    colorectal cancer treatment advances
    Video
    breast cancer overview slideshow
    SLIDESHOW
     
    prostate cancer overview
    SLIDESHOW
    lung cancer overview slideshow
    SLIDESHOW
     
    ovarian cancer overview slideshow
    SLIDESHOW
    Actor Michael Douglas
    Article